Truist lowered the firm’s price target on Incyte (INCY) to $72 from $74 and keeps a Hold rating on the shares. Following the povorcitinib/povo Phase3 results in moderate to severe hidradenitis ...

Incyte (NASDAQ:INCY – Free Report) had its price target reduced by Truist Financial from $74.00 to $72.00 in a report issued on Tuesday,Benzinga reports. They currently have a hold rating on the ...

Guggenheim lowered shares of Incyte (NASDAQ:INCY – Free Report) from a buy rating to a neutral rating in a report issued on Tuesday, Marketbeat Ratings reports. They currently have $92.00 price ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Value investors believe that owning a stock is owning a slice of the underlying business… but this isn’t always true. ...

Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers ...

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Hold rating on Incyte (INCY – Research Report), with a ...

Wells Fargo analyst Derek Archila maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $58.00. The ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Shares of Incyte Corp. INCY slid 8.62% to $62.01 Monday, on what proved to be an all-around positive trading session for the ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...